StockData

Fate Therapeutics vs TScan Therapeutics

FATE and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FATE and TCRX compare

Fate Therapeutics is the larger company, worth 12 times as much as TScan Therapeutics ($122M against $10.2M).

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −23.4% for Fate Therapeutics).

TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −1941% at Fate Therapeutics.

Fate Therapeutics scores higher on the StockData Score (8 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFATETCRX
Size and price
Market cap$122M$10.2M
Share price$1.02$0.151
Change, 1 year5.8%−86.3%
Change, 5 years−98.1%−98.3%
Beta (5Y)3.982.15
Employees161142
StockData Score
Total score8 (better)4
Valuation score33
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S18.8×1.4× (better)
P/B0.8×0.1× (better)
FCF yield−86.4% (better)−1157%
Fair value$1.34$1.36
Margin of safety23.8%88.9% (better)
Growth
Revenue growth (TTM)−23.4%2.2% (better)
Revenue growth, 5Y average−26.7%56.9% (better)
Profitability
Operating margin−2058%−1695% (better)
Net margin−1941%−1655% (better)
FCF margin−1627% (better)−1666%
Return on equity−60.7% (better)−95.8%
Return on invested capital−553%–
Financial health
Debt / equity0.000.47 (better)
Interest coverage–−43.2×
Current ratio4.85 (better)3.37
Altman Z-score−8.99−6.31 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions59.9%53.5%
Held by insiders25.7%32.8%
Insider net buying, 12 months−$336K$146K (better)
Short interest, % of float11.2%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.